<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544345</url>
  </required_header>
  <id_info>
    <org_study_id>UMCLj-AVdromHis</org_study_id>
    <nct_id>NCT04544345</nct_id>
  </id_info>
  <brief_title>Impact of Atrio-ventricular Optimization With His Bundle Pacing on Treatment of Atrio-ventricular Dromotropathy</brief_title>
  <official_title>Impact of Atrio-ventricular Optimization With His Bundle Pacing on Treatment of Atrio-ventricular Dromotropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the clinical and hemodynamic benefit of atrio-ventricular (AV)&#xD;
      resynchronization with His bundle pacing in patients with symptomatic first degree AV block.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The term AV dyssynchrony was introduced by Salden F. and coauthors in 2018. It stands for the&#xD;
      adverse effects of AV dyssynchrony due to PR interval prolongation. According to the ESC and&#xD;
      ACC guidelines, severe first degree AV block is an IIa indication for permanent pacemaker&#xD;
      implantation, yet data on these patients' clinical outcomes are scarce. To independently&#xD;
      determine the impact of AV resynchronization, His bundle pacing will be used to avoid&#xD;
      intraventricular desynchronization.&#xD;
&#xD;
      Symptomatic patients with severe first-degree AV block and echocardiographically proven AV&#xD;
      dyssynchrony will be included in the study.&#xD;
&#xD;
      All patients will receive a dual-chamber pacemaker with an atrial lead positioned in the&#xD;
      right atrium and ventricular lead placed on the bundle of His. In a single-blind cross-over&#xD;
      design, patients will be randomized to AV sequential His bundle pacing with echo-guided AV&#xD;
      optimization or back-up VVI pacing mode. Each study period will last for three months. At the&#xD;
      end of both periods, cardiopulmonary exercise testing, complete echocardiographic study, and&#xD;
      clinical evaluation will be performed.&#xD;
&#xD;
      Peak oxygen uptake and echocardiography-based hemodynamic parameters in both periods will be&#xD;
      compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in exercise capacity</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Measured by peak oxygen consumption on cardiopulmonary exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in left ventricular stroke volume</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Measured by echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in quality of life using the 5 level EQ-5D questionnaire</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>EQ-5D is a standardized measure of health status consisting of 2 pages - the EQ-5D descriptive system (descriptive system with five levels) and the EQ visual analog scale ranging from 0 (worst state) to 100 (best state).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular volume</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>End diastolic volume measured echocardiographicaly with biplane Simpson method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in left atrial volume</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Left atrial volume indexed by body surface area measured by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the measure of left ventricular mechanical dyssynchrony</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Measured by mid-ventricular radial speckle-tracking strain with an anteroseptal to posterior wall delay (AS-P delay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in QRS complex width</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Measured by electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pacing thresholds</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Measured during device check</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sensing of R wave</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Measured during device check</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lead impedance</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Measured during device check</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>Baseline</time_frame>
    <description>Time of fluoroscopy use during device implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>through study completion, an average of one year</time_frame>
    <description>Any of the following adverse events: pocket hematoma, pneumothorax, hemothorax, cardiac tamponade, lead dislocation, lead perforation, cardiac implantable device infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Atrioventricular Block</condition>
  <condition>Atrioventricular Dyssynchrony</condition>
  <arm_group>
    <arm_group_label>His bundle pacing, AV optimized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pacemaker programmed to DDD mode with ventricular lead placed on the bundle of His and echocardiographically optimized AV delay.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Backup VVI pacing</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Pacemaker programmed to ventricular only pacing with low base rate (40/min) to allow intrinsic rhythm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>His bundle pacing, AV optimized</intervention_name>
    <description>A Select Secure 3830 (Medtronic, MN, USA) pacing lead will be placed on the bundle of His. In case of unsuccessful His capture, left bundle branch area pacing is going to be targeted. Pacemaker will be programmed to a low base rate and a high tracking rate to allow for intrinsic sinus rhythm. AV delay will be optimized with echocardiography to the shortest AV delay without truncation of the A wave on transmitral pulse wave doppler.</description>
    <arm_group_label>His bundle pacing, AV optimized</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Backup VVI pacing</intervention_name>
    <description>Pacemaker will be programmed to VVI (ventricular only) mode with low base rate as to allow for intrinsic sinus rhythm without AV optimization.</description>
    <arm_group_label>Backup VVI pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  First OR second degree Mobitz type 1 atrioventricular block with a PR interval &gt; 250&#xD;
             ms&#xD;
&#xD;
          -  left ventricular ejection fraction &gt; 50%&#xD;
&#xD;
          -  echocardiographic criteria of atrioventricular dyssynchrony (diastolic filling time/RR&#xD;
             interval ratio &lt; 0,4 OR fusion of E and A waves OR diastolic mitral regurgitation)&#xD;
&#xD;
          -  symptoms on exertion (dyspnea, palpitations)&#xD;
&#xD;
          -  insufficient shortening of PR interval during exercise (PR interval &gt; 200 ms at heart&#xD;
             rate of 100 beats per minute)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  left ventricular ejection fraction &lt; 50%&#xD;
&#xD;
          -  third degree atrioventricular block&#xD;
&#xD;
          -  atrial fibrillation&#xD;
&#xD;
          -  sinus node disease&#xD;
&#xD;
          -  left bundle branch block&#xD;
&#xD;
          -  right bundle branch block&#xD;
&#xD;
          -  ventricular arrhythmia that indicates implantation of cardioverter defibrillator&#xD;
&#xD;
          -  consumption of drugs that influence atrioventricular conduction&#xD;
&#xD;
          -  active bacterial infection&#xD;
&#xD;
          -  inability to undergo cardiopulmonary exercise test&#xD;
&#xD;
          -  anaemia (haemoglobin concentration &lt; 100 g/L)&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anja Zupan Mežnar, MD, MSc</last_name>
    <phone>+38615228568</phone>
    <email>anja.zupan.meznar@kclj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Žižek, MD, PhD</last_name>
    <phone>+38615228534</phone>
    <email>david.zizek@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Zupan Mežnar, MD, MSc</last_name>
      <phone>+38615228568</phone>
      <email>anja.zupan.meznar@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>David Žižek, MD, PhD</last_name>
      <phone>+38615228534</phone>
      <email>david.zizek@kclj.si</email>
    </contact_backup>
    <investigator>
      <last_name>Anja Zupan Mežnar, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Žižek, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miha Mrak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Salden FCWM, Kutyifa V, Stockburger M, Prinzen FW, Vernooy K. Atrioventricular dromotropathy: evidence for a distinctive entity in heart failure with prolonged PR interval? Europace. 2018 Jul 1;20(7):1067-1077. doi: 10.1093/europace/eux207. Review.</citation>
    <PMID>29186415</PMID>
  </reference>
  <reference>
    <citation>Aro AL, Anttonen O, Kerola T, Junttila MJ, Tikkanen JT, Rissanen HA, Reunanen A, Huikuri HV. Prognostic significance of prolonged PR interval in the general population. Eur Heart J. 2014 Jan;35(2):123-9. doi: 10.1093/eurheartj/eht176. Epub 2013 May 14.</citation>
    <PMID>23677846</PMID>
  </reference>
  <reference>
    <citation>Iliev II, Yamachika S, Muta K, Hayano M, Ishimatsu T, Nakao K, Komiya N, Hirata T, Ueyama C, Yano K. Preserving normal ventricular activation versus atrioventricular delay optimization during pacing: the role of intrinsic atrioventricular conduction and pacing rate. Pacing Clin Electrophysiol. 2000 Jan;23(1):74-83.</citation>
    <PMID>10666756</PMID>
  </reference>
  <reference>
    <citation>European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA), Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace. 2013 Aug;15(8):1070-118. doi: 10.1093/europace/eut206. Epub 2013 Jun 24.</citation>
    <PMID>23801827</PMID>
  </reference>
  <reference>
    <citation>Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, Sharma A; Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002 Dec 25;288(24):3115-23.</citation>
    <PMID>12495391</PMID>
  </reference>
  <reference>
    <citation>Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, Kanj M, Wazni OM, Saliba WI, Varma N, Wilkoff BL, Cantillon DJ. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm. 2016 Dec;13(12):2272-2278. doi: 10.1016/j.hrthm.2016.09.027.</citation>
    <PMID>27855853</PMID>
  </reference>
  <reference>
    <citation>Sharma PS, Dandamudi G, Naperkowski A, Oren JW, Storm RH, Ellenbogen KA, Vijayaraman P. Permanent His-bundle pacing is feasible, safe, and superior to right ventricular pacing in routine clinical practice. Heart Rhythm. 2015 Feb;12(2):305-12. doi: 10.1016/j.hrthm.2014.10.021. Epub 2014 Oct 22.</citation>
    <PMID>25446158</PMID>
  </reference>
  <reference>
    <citation>Abdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, Oren JW, Dandamudi G, Vijayaraman P. Clinical Outcomes of His Bundle Pacing Compared to Right Ventricular Pacing. J Am Coll Cardiol. 2018 May 22;71(20):2319-2330. doi: 10.1016/j.jacc.2018.02.048. Epub 2018 Mar 10.</citation>
    <PMID>29535066</PMID>
  </reference>
  <reference>
    <citation>Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009 Oct 1;361(14):1329-38. doi: 10.1056/NEJMoa0906431. Epub 2009 Sep 1.</citation>
    <PMID>19723701</PMID>
  </reference>
  <reference>
    <citation>Kutyifa V, Stockburger M, Daubert JP, Holmqvist F, Olshansky B, Schuger C, Klein H, Goldenberg I, Brenyo A, McNitt S, Merkely B, Zareba W, Moss AJ. PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy. Circ Arrhythm Electrophysiol. 2014 Aug;7(4):645-51. doi: 10.1161/CIRCEP.113.001299. Epub 2014 Jun 24.</citation>
    <PMID>24963007</PMID>
  </reference>
  <reference>
    <citation>Joshi NP, Stopper MM, Li J, Beshai JF, Pavri BB. Impact of baseline PR interval on cardiac resynchronization therapy outcomes in patients with narrow QRS complexes: an analysis of the ReThinQ Trial. J Interv Card Electrophysiol. 2015 Aug;43(2):145-9. doi: 10.1007/s10840-015-9999-y. Epub 2015 Apr 29.</citation>
    <PMID>25921348</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Guo J, Hou X, Wang Y, Qian Z, Li K, Ge P, Zou J. Comparison of the effects of selective and non-selective His bundle pacing on cardiac electrical and mechanical synchrony. Europace. 2018 Jun 1;20(6):1010-1017. doi: 10.1093/europace/eux120.</citation>
    <PMID>28575215</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Anja Zupan Mežnar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>AV block</keyword>
  <keyword>His bundle pacing</keyword>
  <keyword>AV dyssynchrony</keyword>
  <keyword>AV optimization</keyword>
  <keyword>AV dromotropathy</keyword>
  <keyword>First degree AV block</keyword>
  <keyword>Peak oxygen uptake</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrioventricular Block</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

